LifeStance Health Group (NASDAQ:LFST) Stock Price Expected to Rise, BTIG Research Analyst Says

Posted by Brenda Bartman on Nov 7th, 2026

LifeStance Health Group (NASDAQ:LFST – Get Free Report) had its price target hoisted by BTIG Research from $18.00 to $20.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research‘s target price would indicate a potential upside of 45.24% from the stock’s current price.

A number of other analysts also recently weighed in on LFST. JPMorgan Chase & Co. boosted their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Canaccord Genuity Group lifted their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Barclays upped their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Finally, KeyCorp increased their price target on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.75.

Get Our Latest Stock Analysis on LFST

LifeStance Health Group Price Performance

LifeStance Health Group stock traded up $0.34 during midday trading on Thursday, reaching $13.77. 4,924,487 shares of the stock traded hands, compared to its average volume of 2,978,738. The stock’s fifty day moving average is $12.62 and its 200-day moving average is $9.49. LifeStance Health Group has a 12 month low of $5.87 and a 12 month high of $15.66. The stock has a market cap of $5.26 billion, a P/E ratio of 72.48 and a beta of 1.35. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $455.86 million for the quarter, compared to the consensus estimate of $431.59 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%. The company’s revenue was up 25.3% on a year-over-year basis. As a group, equities research analysts anticipate that LifeStance Health Group will post 0.17 EPS for the current year.

Insider Transactions at LifeStance Health Group

In other news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the sale, the insider directly owned 98,101,407 shares in the company, valued at approximately $1,041,836,942.34. This represents a 12.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Lisa Miller sold 47,912 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the sale, the chief operating officer directly owned 281,289 shares of the company’s stock, valued at $3,051,985.65. This represents a 14.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 13,777,580 shares of company stock worth $146,433,781. 3.50% of the stock is currently owned by company insiders.

Institutional Trading of LifeStance Health Group

A number of hedge funds and other institutional investors have recently bought and sold shares of LFST. BlackRock Inc. purchased a new stake in shares of LifeStance Health Group during the second quarter valued at $389,293,000. Wellington Management Group LLP purchased a new position in LifeStance Health Group in the 2nd quarter worth about $30,881,000. Jennison Associates LLC increased its stake in LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after buying an additional 2,843,388 shares during the period. Dimensional Fund Advisors LP lifted its holdings in LifeStance Health Group by 16.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after buying an additional 1,461,215 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in LifeStance Health Group during the 2nd quarter valued at about $14,987,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

LifeStance Health Group Company Profile

(Get Free Report)

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.